CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 187 filers reported holding CRISPR THERAPEUTICS AG in Q3 2018. The put-call ratio across all filers is 2.47 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $510,000 | -27.6% | 3,334 | -60.4% | 0.00% | -33.3% |
| Q3 2020 | $704,000 | +13.7% | 8,423 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $619,000 | +79.9% | 8,423 | +3.9% | 0.00% | +50.0% |
| Q1 2020 | $344,000 | -30.4% | 8,109 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $494,000 | +48.8% | 8,109 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $332,000 | -14.2% | 8,109 | -1.2% | 0.00% | 0.0% |
| Q2 2019 | $387,000 | +31.6% | 8,209 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $294,000 | +12.6% | 8,209 | +84.9% | 0.00% | +100.0% |
| Q2 2018 | $261,000 | +29.2% | 4,440 | +0.2% | 0.00% | 0.0% |
| Q1 2018 | $202,000 | – | 4,430 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |